Clinical markers associated with glycaemic response to dipeptidyl peptidase-4 inhibitor therapy

被引：2
|
作者：
Yamagishi, Sho-ichi [1 ]
机构：
[1] Kurume Univ, Sch Med, Dept Pathophysiol & Therapeut Diabet Vasc Complic, Kurume, Fukuoka 8300011, Japan
来源：
DIABETES-METABOLISM RESEARCH AND REVIEWS | 2018年 / 34卷 / 07期
关键词：
advanced glycation end products; DPP-4; insulin resistance; oxidative stress; GLYCATION END-PRODUCTS; DPP-4; OBESITY; GLP-1;
D O I：
10.1002/dmrr.3024
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid
    Sun, Linli
    Wang, Chunxia
    Wu, Cuifang
    Zhou, Yulu
    Wang, Chunjiang
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (02) : 205 - 212
  • [42] Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor reverses diabetes in NOD mice
    Suarez-Pinzon, Wilma L.
    Cembrowski, George S.
    Rabinovitch, Alex
    DIABETES, 2008, 57 : A444 - A444
  • [43] Dipeptidyl Peptidase-4 Inhibitor Improves Steatohepatitis by Targeting Trail Receptor-Mediated Apoptosis Under Modulation of Dipeptidyl Peptidase-4 Expression
    Lee, Sejeong
    Lee, Minyoung
    Shin, Eugene
    Kim, Young-Eun
    Kang, Eun Seok
    Cha, Bong-Soo
    DIABETES, 2020, 69
  • [44] Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events
    Rahman, Md Motiur
    Scalese, Michael J.
    Hansen, Richard A.
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (07) : 563 - 569
  • [45] Population Pharmacokinetic Analysis of Dutogliptin, a Selective Dipeptidyl Peptidase-4 Inhibitor
    Marier, Jean-Francois
    Mouksassi, Mohamad-Samer
    Gosselin, Nathalie H.
    Li, Jianke
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (04): : 297 - 304
  • [46] Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
    Kim, Ye An
    Yoo, Won Sang
    Hong, Eun Shil
    Ku, Eu Jeong
    Park, Kyeong Seon
    Lim, Soo
    Cho, Young Min
    Park, Kyong Soo
    Jang, Hak Chul
    Choi, Sung Hee
    DIABETES & METABOLISM JOURNAL, 2015, 39 (06) : 489 - 497
  • [47] Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: evaluation of clinical course and treatment response
    Tzanani, Ido
    Tzachy-Suissa, Inbar
    Barzilai, Aviv
    Pavlotsky, Felix
    Lyakhovitsky, Anna
    Baum, Sharon
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2023, 48 (08) : 873 - 880
  • [48] Epitope-spreading phenomena in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid
    Garcia-Diez, I.
    Espana, A.
    Iranzo, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (05) : 1267 - 1268
  • [49] Association between Add-On Dipeptidyl Peptidase-4 Inhibitor Therapy and Diabetic Retinopathy Progression
    Kang, Eugene Yu-Chuan
    Kang, Chunya
    Wu, Wei-Chi
    Sun, Chi-Chin
    Chen, Kuan-Jen
    Lai, Chi-Chun
    Chen, Tien-Hsing
    Hwang, Yih-Shiou
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (13)
  • [50] Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials
    Monami, Matteo
    Cremasco, Francesco
    Lamanna, Caterina
    Marchionni, Niccolo
    Mannucci, Edoardo
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2011, 27 (04) : 362 - 372
12345